Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 96.6 B
The data is delayed by 15 minutes.
AGN is in the long-term up 591% in 19 years.
Description: Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||395.56 M||EPS||EPS Growth - 4 Quarters||115.47%||EPS Growth - Q/Q||75.5%|
|EPS Growth - Y/Y||58.22%||Sales Growth - 4 Quarters||16.06%||Sales Growth - Q/Q||5.14%||P/E|
|P/E To EPS Growth||0.57||P/S||13.35||P/BV||12.46||Price/Cash Per Share||19.45|
|Price/Free Cash Flow||57.37||ROA||12.28%||ROE||19.66%||ROI||14.05%|
|Current Ratio||4.41||Quick Ratio||4.22||Long Term Debt/Equity||0.39||Debt Ratio||0.2|
|Gross Margin||88.36%||Operating Margin||27.76%||Net Profit Margin||21.06%||Dividend Payout Ratio||-3.91%|
|Cash From Financing Activities||Cash From Investing Activities||183.4 M||Cash From Operating Activities||144.6 M||Gross Profit||1.7 B|
|Net Profit||694.2 M||Operating Profit||626.7 M||Total Assets||12.42 B||Total Current Assets||6.87 B|
|Total Current Liabilities||1.56 B||Total Debt||2.09 B||Total Liabilities||4.66 B||Total Revenue||1.91 B|
|High 52 week||254.35||Low 52 week||163.58||Last close||181.33||Last change||0.94%|
|RSI||76.15||Average true range||4||Beta||0.66||Volume||3.21 M|
|Simple moving average 20 days||5.72%||Simple moving average 50 days||5.79%||Simple moving average 200 days||-14.33%|
|Performance Week||2.38%||Performance Month||6.1%||Performance Quart||-2.72%||Performance Half||-26.68%|
|Performance Year||-14.39%||Performance Year-to-date||10.85%||Volatility daily||1.51%||Volatility weekly||3.37%|
|Volatility monthly||6.91%||Volatility yearly||23.95%||Relative Volume||226.12%||Average Volume||3.42 M|
|New High||New Low|
2019-11-12 17:12:59 | AbbVie Sells $30 Billion of Bonds to Fund Allergan Acquisition
2019-11-12 14:08:07 | Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co.
2019-11-12 06:46:13 | AbbVie sells $30bn of bonds to finance Allergan takeover
2019-11-12 05:00:00 | AbbVie Eyes Up to $28 Billion Bond Sale to Finance Allergan Deal: Report
2019-11-11 17:13:38 | Allergan CEO on Innovation and Blockbuster Biopharmaceuticals
2019-11-11 10:32:03 | The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
2019-11-11 07:30:00 | Allergan Receives FDA Qualified Infectious Disease Product QIDP Designation And Fast Track Designation For ATM-AVI Aztreonam And Avibactam For Antibiotic-Resistant Gram-Negative Infections
2019-11-08 09:59:02 | Teva TEVA Q3 Earnings Miss, Stock Up on Guidance Increase
2019-11-08 09:38:08 | With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback
2019-11-08 09:26:02 | Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed
2019-11-07 10:18:09 | AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's new sr. notes; stable outlook
2019-11-05 18:16:26 | Vanguard Health Care Fund Sells Out of Allergan
2019-11-05 15:57:07 | 2 Stocks to Watch Tuesday
2019-11-05 11:02:04 | Allergan AGN Meets Q3 Earnings Estimates, Ups '19 Sales View
2019-11-05 10:48:59 | Allergan's Q3 Sales Get A Facelift From Botox; AbbVie Deal On Track
2019-11-05 08:15:01 | Allergan AGN Q3 Earnings Meet Estimates
2019-11-05 07:38:00 | Allergan's stock gains after adjusted profit, revenue beat expectations
2019-11-05 07:00:00 | Allergan Reports Third Quarter 2019 Financial Results
2019-11-05 04:40:00 | [video]Allergan Tops Q3 Earnings, Bumps 2019 Sales Guidance Amid AbbVie Takeover
2019-11-04 13:08:56 | Allergan Q3 Earnings Preview
2019-11-04 12:28:00 | Marine algae keys Chinese claim to Alzheimer’s breakthrough
2019-11-04 12:27:00 | Day Ahead: Top 3 Things to Watch
2019-11-04 11:23:04 | Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
2019-11-04 10:00:03 | Should You Buy Allergan AGN Ahead of Earnings?
2019-11-04 09:15:02 | Allergan AGN Hits 52-Week High, Can the Run Continue?
2019-11-01 16:21:10 | AbbVie Stock Jumps On Strong Quarter As Allergan Takeover Looms
2019-11-01 14:47:06 | AbbVie ABBV Beats on Q3 Earnings & Sales, Tweaks EPS View
2019-11-01 11:07:03 | WIll Allergan AGN Beat Estimates This Earnings Season?
2019-11-01 11:05:03 | Is a Beat in the Cards for Mallinckrodt MNK in Q3 Earnings?
2019-11-01 10:52:02 | Ironwood IRWD Beats on Q3 Earnings & Revenues, Ups '19 View
2019-11-01 10:10:07 | AbbVie says multiple parties vying for assets related to Allergan deal approval
2019-11-01 09:04:00 | AbbVie Delivers on Earnings and Raises Forecast
2019-11-01 08:05:07 | Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
2019-11-01 05:35:00 | [video]AbbVie Posts Stronger-Than-Expected Earnings, Lifts Forecast
2019-10-30 11:46:03 | Mylan MYL to Report Q3 Earnings: What's in the Offing?
2019-10-29 10:33:02 | Allergan AGN Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2019-10-28 10:24:15 | RPT-UPDATE 1-Allergan settles Alzheimer's therapy lawsuit for $750 million
2019-10-28 09:00:00 | FDA Approves Medicines360's LILETTA® levonorgestrel-releasing intrauterine system 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
2019-10-28 08:31:00 | Forest Resolves Antitrust Class Action Litigation with Direct Purchasers of Namenda
2019-10-27 19:46:00 | China could quickly become the world’s largest antidepressant market, but hurdles remain
2019-10-25 11:10:03 | What's in the Cards for AbbVie ABBV This Earnings Season?
2019-10-25 10:28:09 | Allergan Finance, LLC -- Moody's assigns Baa2 to AbbVie's exchange note offering
2019-10-25 10:10:02 | Will Allergan AGN Beat Estimates Again in Its Next Earnings Report?
2019-10-25 07:00:00 | Allergan Declares Fourth Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share